Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14
- Analyst Recommendation: Lake Street analyst Thomas Flaten has maintained a Buy rating for DiaMedica Therapeutics.
- Price Target Increase: The price target for the company's stock has been raised from $11 to $14.
Trade with 70% Backtested Accuracy
Analyst Views on DMAC
About DMAC
About the author
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Incentive Options: On January 15, 2026, DiaMedica granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on the grant date, ensuring that employees have a strong financial incentive to remain with the company long-term.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments thereafter, designed to encourage continued service and enhance employee loyalty.
- Strategic Focus: DiaMedica is dedicated to developing innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, and this stock option grant not only attracts talent but also supports its long-term growth in the biopharmaceutical sector.
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Options Grant: On January 15, 2026, DiaMedica Therapeutics granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on January 15, 2026, indicating the company's commitment to employee incentives.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments, ensuring long-term incentives for employees who continue their service with the company.
- Strategic Implications: This options grant not only enhances the company's ability to attract and retain talent but also reflects DiaMedica's ongoing commitment to growth in the clinical-stage biopharmaceutical sector and investment in its workforce.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
DiaMedica Engages FDA for DM199 Preclinical Study Clarity
- FDA Meeting Outcomes: DiaMedica's in-person meeting with the FDA confirmed the need for an additional non-clinical study to evaluate DM199 for preeclampsia, with results expected by Q2 2026, thereby providing crucial regulatory clarity for the IND submission.
- Clinical Trial Progress: The ongoing Phase 2 trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia, with interim data showing significant reductions in blood pressure and no placental transfer, indicating promising safety and efficacy.
- R&D Strategy: As the first pharmaceutical-grade recombinant form of human tissue kallikrein-1, DM199 targets preeclampsia, fetal growth restriction, and acute ischemic stroke, showcasing potential competitiveness in the global market, particularly in Asia.
- Future Outlook: DiaMedica plans to maintain ongoing engagement with the FDA to advance DM199's development, aiming to provide new treatment options for women facing preeclampsia, aligning with global demands for improved maternal and neonatal health.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
DiaMedica Therapeutics to Attend Jefferies Global Healthcare Conference in London
Company Participation: DiaMedica Therapeutics Inc. will have its President and CEO, Rick Pauls, participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025, where he will deliver a corporate presentation and engage in one-on-one investor meetings.
Presentation Details: The corporate presentation is scheduled for November 20, 2025, from 10:00 to 10:25 AM GMT.
Company Focus: DiaMedica is a clinical-stage biopharmaceutical company dedicated to developing treatments for serious conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke.
Lead Candidate: The company's lead candidate, DM199, is the first synthetic form of the KLK1 protein being clinically studied in the U.S. for acute ischemic stroke, with established therapeutic use in China.
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Incentive Options: On January 15, 2026, DiaMedica granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on the grant date, ensuring that employees have a strong financial incentive to remain with the company long-term.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments thereafter, designed to encourage continued service and enhance employee loyalty.
- Strategic Focus: DiaMedica is dedicated to developing innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, and this stock option grant not only attracts talent but also supports its long-term growth in the biopharmaceutical sector.
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Options Grant: On January 15, 2026, DiaMedica Therapeutics granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on January 15, 2026, indicating the company's commitment to employee incentives.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments, ensuring long-term incentives for employees who continue their service with the company.
- Strategic Implications: This options grant not only enhances the company's ability to attract and retain talent but also reflects DiaMedica's ongoing commitment to growth in the clinical-stage biopharmaceutical sector and investment in its workforce.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
DiaMedica Engages FDA for DM199 Preclinical Study Clarity
- FDA Meeting Outcomes: DiaMedica's in-person meeting with the FDA confirmed the need for an additional non-clinical study to evaluate DM199 for preeclampsia, with results expected by Q2 2026, thereby providing crucial regulatory clarity for the IND submission.
- Clinical Trial Progress: The ongoing Phase 2 trial of DM199 in South Africa has dosed over 30 women with late-stage preeclampsia, with interim data showing significant reductions in blood pressure and no placental transfer, indicating promising safety and efficacy.
- R&D Strategy: As the first pharmaceutical-grade recombinant form of human tissue kallikrein-1, DM199 targets preeclampsia, fetal growth restriction, and acute ischemic stroke, showcasing potential competitiveness in the global market, particularly in Asia.
- Future Outlook: DiaMedica plans to maintain ongoing engagement with the FDA to advance DM199's development, aiming to provide new treatment options for women facing preeclampsia, aligning with global demands for improved maternal and neonatal health.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
DiaMedica Therapeutics to Attend Jefferies Global Healthcare Conference in London
Company Participation: DiaMedica Therapeutics Inc. will have its President and CEO, Rick Pauls, participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025, where he will deliver a corporate presentation and engage in one-on-one investor meetings.
Presentation Details: The corporate presentation is scheduled for November 20, 2025, from 10:00 to 10:25 AM GMT.
Company Focus: DiaMedica is a clinical-stage biopharmaceutical company dedicated to developing treatments for serious conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke.
Lead Candidate: The company's lead candidate, DM199, is the first synthetic form of the KLK1 protein being clinically studied in the U.S. for acute ischemic stroke, with established therapeutic use in China.
